Ikarian Capital’s Amicus Therapeutics FOLD Stock Holding History

Ikarian Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-164,174	Closed	-$1.9M	–	203
2021 Q4	$1.9M	Sell	164,174 -250,000	-60%	-$2.79M	0.28%	66
2021 Q3	$3.95M	Buy	414,174 +72,674	+21%	+$743K	0.28%	80
2021 Q2	$3.29M	Hold	341,500	–	–	0.27%	90
2021 Q1	$3.37M	Buy	+341,500	New	+$5.29M	0.11%	161

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's FOLD Position: Q1 2022 in Review

Ikarian Capital sold out of Amicus Therapeutics (FOLD) in Q1 2022, closing a stake of 164,174 shares — an estimated $1.9M sold.

Ikarian Capital first reported a position in FOLD in Q1 2021 and held it in 4 quarters. The position peaked at $3.95M in Q3 2021. 217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

Ikarian Capital reported no remaining Amicus Therapeutics position as of Q1 2022 after selling out during the quarter.
Ikarian Capital sold 164,174 Amicus Therapeutics shares in Q1 2022, an estimated $1.9M.
Ikarian Capital first reported a position in Amicus Therapeutics in Q1 2021 and held it in 4 quarters.
Ikarian Capital's Amicus Therapeutics position peaked at $3.95M in Q3 2021.
217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.